ReviewNaunyn-Schmiedeberg's archives of pharmacology2026
Pharmacological features of mesoionic compounds: antitumoral effects and bioenergetic disruption of sydnones and 1,3,4-thiadiazolium derivatives.
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesoionic compounds are five-membered heterocyclic betaines that cannot be satisfactorily represented by a single covalent or polar structure. Because their positive and negative charges are delocalized over separate regions of the ring, they yield a net-neutral molecule with a high dipole moment. This unique electronic configuration confers amphiphilic character and pronounced affinity for biological membranes, including mitochondria, underlying a broad pharmacological profile that includes antitumoral, anti-inflammatory and analgesic activities. Among the several mesoionic scaffolds, sydnones (1,2,3-oxadiazolium-5-olate) and 1,3,4-thiadiazolium derivatives have been the most extensively studied, drawing particular attention to their pronounced antineoplastic activity against melanoma, hepatocellular carcinoma, breast cancer and glioblastoma models. Their anticancer effects are closely linked to mitochondrial bioenergetic disruption, including uncoupling of oxidative phosphorylation, inhibition of respiratory complexes, dissipation of the mitochondrial membrane potential, and stimulation of F1Fo-ATPase activity, which together cause ATP depletion, redox imbalance, and apoptosis induction. This review provides a comprehensive analysis of the structural features that govern these biological properties, the antitumor efficacy of sydnones and thiadiazolium derivatives across various cancer models, and the underlying mitochondrial mechanisms. By integrating chemical, pharmacological, and bioenergetic perspectives, this article highlights the potential of mesoionic compounds as versatile scaffolds for the anticancer drug development, emphasizing their preclinical antitumoral activities, the mechanisms related to cell bioenergetics, and the challenges to improve the bioviability through nanotechnologies.
Indexed as
Identifiers
42859209What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.